Company intelligence
CRYOPDP
Lifescience & Healthcare Supply Chain Solutions
About CRYOPDP
Everything began with a commitment to serve the life sciences and healthcare industries by offering global transport and innovative temperature-controlled logistics solutions. Being one of the market leaders in our sector and dedicated to the clinical trial and cell & gene therapy communities, we are operating in more than 150 countries intending to improve the health of people around the world. Truly focused on our customer and patient needs, we, through a dedicated team, plan, manage and implement a tailor-made temperature-controlled solution to fit your requirements and business goals. Count on us to deliver your life-saving goods worldwide - Count on CRYOPDP!
Verified activity
Signals from CRYOPDP
9 published signals
Research & Knowledge
CRYOPDP tested FLASH proton therapy in 10 people with painful bone metastases in the chest, near the heart, lungs and spinal cord.
Reported by CRYOPDP
Products & Services
CRYOPDP coordinates collection and delivery timings, handling instructions, site access, communication, and monitoring around sensitive shipments with a White-Glove logistics service.
Reported by CRYOPDP
Research & Knowledge
CRYOPDP published the results of the first patient dosing in TOPICAL, a trial testing POLB 001 in people with relapsed or refractory multiple myeloma receiving teclistamab.
Reported by CRYOPDP
Research & Knowledge
CRYOPDP announced that the first patient has joined the DELUMA randomised phase 2 trial for HER2-negative metastatic breast cancer patients whose disease has progressed after prior treatment.
Reported by CRYOPDP
Research & Knowledge
CRYOPDP managed the temperature-controlled transport of tumour samples to testing laboratories for the phase 3 XPORT-EC-042 trial.
Reported by CRYOPDP
Research & Knowledge
CRYOPDP completed enrolment in a phase 1–2a trial of EO1001, an oral treatment developed to treat ErbB-driven tumours in the brain and elsewhere in the body.
Reported by CRYOPDP
Presence & Recognition
CRYOPDP will be attending the ACE - Clinical Trials Supply Summit in London on 9-10 September, taking place at Booth #2.
Reported by CRYOPDP
Research & Knowledge
CRYOPDP announced that the TARGET-D 203 phase 2 trial has begun treating patients with KRAS G12D-mutated metastatic colorectal cancer.
Reported by CRYOPDP
Products & Services
CRYOPDP provides a single logistics framework for managing trial supply, deliveries and documentation for each study arm.
Reported by CRYOPDP